We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+1.29%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$330M
AUM Growth
+$135M
Cap. Flow
+$130M
Cap. Flow %
39.57%
Top 10 Hldgs %
74.15%
Holding
31
New
9
Increased
11
Reduced
2
Closed
8

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$24.8M
2
UNH icon
UnitedHealth
UNH
+$23.2M
3
ASND icon
Ascendis Pharma A/S
ASND
+$18.8M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$17.8M
5
ARGX icon
argenx
ARGX
+$17.4M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$24.3M
2
MCK icon
McKesson
MCK
+$18.1M
3
GILD icon
Gilead Sciences
GILD
+$10M
4
ILMN icon
Illumina
ILMN
+$9.58M
5
INSM icon
Insmed
INSM
+$7.77M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$37.3B
$34.3M 10.41%
2,046,846
+985,838
+93% +$15.9M
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$12.8B
$29.6M 8.98%
97,765
+59,896
+158% +$17.8M
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$35.7B
$29.2M 8.86%
+89,525
New +$24.8M
ARGX icon
4
argenx
ARGX
$53.8B
$26.3M 8%
47,793
+29,949
+168% +$17.4M
ASND icon
5
Ascendis Pharma A/S
ASND
$17.1B
$25.5M 7.73%
147,642
+115,317
+357% +$18.8M
SLNO
6
DELISTED
Soleno Therapeutics
SLNO
$24.2M 7.34%
288,880
+53,960
+23% +$4.04M
VRNA
7
DELISTED
Verona Pharma
VRNA
$20.5M 6.22%
+216,578
New +$16M
INSP icon
8
Inspire Medical Systems
INSP
$1.46B
$19.4M 5.88%
149,244
+70,432
+89% +$10.2M
UNH icon
9
UnitedHealth
UNH
$387B
$18.9M 5.74%
+60,584
New +$23.2M
AXSM icon
10
Axsome Therapeutics
AXSM
$11.8B
$16.5M 5%
157,861
+56,621
+56% +$6M
EOLS icon
11
Evolus
EOLS
$377M
$11.4M 3.46%
1,239,031
+917,229
+285% +$9.38M
ABBV icon
12
AbbVie
ABBV
$450B
$10.3M 3.14%
+55,661
New +$10.3M
VERA icon
13
Vera Therapeutics
VERA
$2.76B
$9.73M 2.95%
413,114
+262,907
+175% +$5.91M
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
$8.98M 2.72%
+1,014,456
New +$8.91M
PRAX icon
15
Praxis Precision Medicines
PRAX
$8.77B
$8.22M 2.49%
195,432
+111,773
+134% +$4.26M
TARS icon
16
Tarsus Pharmaceuticals
TARS
$2.61B
$7.2M 2.18%
+177,656
New +$8M
ISRG icon
17
Intuitive Surgical
ISRG
$122B
$6.97M 2.11%
+12,824
New +$6.71M
LEGN icon
18
Legend Biotech
LEGN
$4.31B
$6.15M 1.87%
+173,260
New +$5.61M
NUVL
19
DELISTED
Nuvalent
NUVL
$5.8M 1.76%
75,973
-19,852
-21% -$1.45M
BHVN icon
20
Biohaven
BHVN
$2.32B
$3.83M 1.16%
+271,367
New +$4.84M
KRRO icon
21
Korro Bio
KRRO
$177M
$3.48M 1.06%
139,493
+11,112
+9% +$160K
WGS icon
22
GeneDx Holdings
WGS
$1.88B
$3.04M 0.92%
32,931
-25,214
-43% -$1.98M
FEMY icon
23
Femasys
FEMY
$9.09M
$29.6K 0.01%
1,530
– –
BPMC
24
DELISTED
Blueprint Medicines
BPMC
– –
-50,000
Closed -$4.43M
CI icon
25
Cigna
CI
$74.5B
– –
-73,905
Closed -$24.3M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
LS
Leelyn Smith Geneva, Illinois $713M AUM 17.46% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Tri Locum Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Tri Locum Partners held 31 positions worth $330M, up 69% from $195M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Tri Locum Partners deployed $130M of net new capital in Q2 2025, opening 9 new positions and adding to 11 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 89,525 shares worth $29.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was GeneDx Holdings, an estimated $1.98M trimmed.

  • Tri Locum Partners's largest Q2 2025 buy was Alnylam Pharmaceuticals: 89,525 shares worth $29.2M.
  • Tri Locum Partners added most to Ascendis Pharma A/S in Q2 2025, an estimated $18.8M increase.
  • Tri Locum Partners's biggest Q2 2025 reduction was GeneDx Holdings, cutting an estimated $1.98M.
  • Tri Locum Partners fully exited Cigna in Q2 2025, selling an estimated $24.3M.
  • Tri Locum Partners's ten largest holdings make up 74% of its $330M portfolio in Q2 2025.
  • Tri Locum Partners opened 9 new positions and closed 8 in Q2 2025.
  • Tri Locum Partners's portfolio value rose 69% quarter-over-quarter to $330M.

Based on Tri Locum Partners's 13F filing for Q2 2025, filed 14 Aug 2025.